NRSNW (NeuroSense Therapeutics) Short Interest


NRSNW NeuroSense Therapeutics Ltd NRSNW
29 GF Score
Price $0.21
! 2 Warning Signs
View Full Analysis

What is NeuroSense Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

NRSNW vs SNTI, LSTA, DYAI: Short Interest Comparison

For the Biotechnology subindustry, NeuroSense Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuroSense Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuroSense Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where NeuroSense Therapeutics's Short Interest falls into.


NRSNW
29GF Score
NeuroSense Therapeutics Ltd NRSNW
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroSense Therapeutics Business Description

Other Exchanges NRSN:USAH1Z:Germany
Address 11 HaMenofim Street, Building B, Herzliya, ISR, 4672562
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
29GF Score

Get the complete analysis for NRSNW

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.21
Price